LeMaitre Vascular, Inc. LMAT
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -0.20%
- 1 year
- -8.59%
- Open
- 85.53
- Prev close
- 85.27
- Mkt cap
- 1.85B
- Vol
- 427.37K
- Avg vol
- 326.05K
- EPS
- 2.85
- P/E
- 28.40
- Div yield
- 1.17%
More statistics
- Low
- 80.03
- High
- 85.53
- Forward P/E
- 25.46
- Beta
- 0.47
- Short ratio
- 6.66
- Inst. own
- 104.08%
- Dividend
- 1.00
- Ex-div date
- Aug 19, 2026
- Earnings
- Nov 4, 2026
- 50-d avg
- 81.23
- 200-d avg
- 94.49
- 1y target
- 107.00
News
1 day ago seekingalpha.com
Dividend Income Report: +15.25% And A Listener's Portfolio Roast
This month I tried something different on the podcast - a listener sent me one of his portfolios and asked me to roast it. He holds 29 stocks with roughly equal weight, so I built a mock $100,000…
2 weeks ago globenewswire.com
LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026
BURLINGTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2026 financial results on Wednesday, November 4,…
1 month ago seekingalpha.com
LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition Machine
LeMaitre Vascular is rated a "Strong Buy" due to its robust M&A-driven business model, high margins, and recent valuation compression. LMAT's strategic shift to larger, higher-multiple acquisitions…
1 month ago prnewswire.com
LeMaitre Vascular Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Customer Data Is Exposed
National class action law firm offers free, confidential case evaluations to LeMaitre Vascular investors, tenants, partners, and others whose personal information may have been exposed in the…
-
1 month ago benzinga.com
L3Harris Technologies Receives 7-Year, $4.7B Lockheed Martin Contract To Produce Propulsion Systems For PAC-3 Missile Segment Enhancement Interceptor
L3Harris Technologies (NYSE: LHX) has received an undefinitized contract award from Lockheed Martin, valued at $4.7 billion over seven years, to produce propulsion systems for the PAC-3® Missile…
2 months ago zacks.com
PAHC or LMAT: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks is more…
2 months ago globenewswire.com
LeMaitre to Participate at Upcoming Investor Conferences in September
BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
2 months ago seekingalpha.com
Dividend Champion, Contender, And Challenger Highlights: Week August 16
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
2 months ago zacks.com
GEHC or LMAT: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the…
2 months ago seekingalpha.com
LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut
LeMaitre Vascular remains a Buy after a 31% pullback, though I have trimmed my price target to $95-$100 for year-end 2027. The Q2 2026 miss was tied to currency, export blockages, and tissue…
2 months ago globenewswire.com
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
BURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will hold investor meetings at the 11th Annual Needham Virtual MedTech &…
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) stock increased by 107.0% to $2.65 during Wednesday's regular session. The company's market cap stands at $60.6 million. Bluejay Diagnostics (NASDAQ:BJDX)…
-
2 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Lowers Price Target to $94
Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight and lowers the price target from $104 to $94.
2 months ago seekingalpha.com
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
LeMaitre Vascular Q2 Earnings Call Highlights
LeMaitre Vascular NASDAQ: LMAT reported second-quarter 2026 results marked by 10% organic revenue growth, record operating income and continued expansion of its Artegraft product line, while foreign…
2 months ago zacks.com
LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Lag Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.74 per share, missing the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.6 per share a year ago.
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday's after-market session. American Well (NYSE:AMWL) stock rose 12.76% to $11.75. The market value of their…
-
2 months ago benzinga.com
LeMaitre Vascular Sees Q4 GAAP EPS $0.75-$0.81 vs $0.78 Est; Sees Sales $71.100M-$73.100M vs $72.745M Est
LeMaitre Vascular (NASDAQ:LMAT) is looking for Q4 GAAP EPS of $0.75-$0.81 vs $0.78 analyst estimate. sees sales of $71.100 million-$73.100 million vs $72.745 million analyst estimate.
-
2 months ago benzinga.com
LeMaitre Vascular Sees Q3 GAAP EPS $0.66-$0.71 vs $0.73 Est; Sees Sales $66.300M-$68.300M vs $69.246M Est
LeMaitre Vascular (NASDAQ:LMAT) is looking for Q3 GAAP EPS of $0.66-$0.71 vs $0.73 analyst estimate. sees sales of $66.300 million-$68.300 million vs $69.246 million analyst estimate.
-
2 months ago benzinga.com
LeMaitre Vascular Lowers FY2026 GAAP EPS Guidance from $2.93-$3.08 to $2.84-$2.94 vs $2.97 Est; Lowers FY2026 Sales Guidance from $277.000M-$283.000M to $274.300M-$278.300M vs $279.948M Est
LeMaitre Vascular (NASDAQ:LMAT) lowers FY2026 GAAP EPS guidance from $2.93-$3.08 to $2.84-$2.94 vs $2.97 analyst estimate. Lowers FY2026 sales outlook from $277.000 million-$283.000 million to…
-
2 months ago benzinga.com
LeMaitre Vascular Q2 EPS $0.74 Misses $0.79 Estimate, Sales $70.382M Miss $70.973M Estimate
LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.74 per share which missed the analyst consensus estimate of $0.79 by 6.33 percent. This is a 23.33 percent increase over earnings of…
2 months ago globenewswire.com
LeMaitre Q2 2026 Financial Results
BURLINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a…
3 months ago globenewswire.com
LeMaitre Will Announce Second Quarter 2026 Earnings Results on August 4, 2026
BURLINGTON, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2026 financial results on Tuesday, August 4, 2026,…
4 months ago seekingalpha.com
We Have A Valuation Problem - May Dividend Income Report
I don't love valuation models because they rely on assumptions, and assumptions can be dangerous. But we still need to pay attention. I sold my position in BIPC not because I don't like the stock or…
5 months ago zacks.com
Casey's & 3 More Stocks With Strong Interest Coverage to Buy Now
CASY, CLS, PNTG and LMAT stand out for strong interest coverage as borrowing costs rise, with solid sales/EPS growth estimates and big one-year gains.
5 months ago zacks.com
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
5 months ago globenewswire.com
LeMaitre to Participate at Upcoming Investor Conferences in June
BURLINGTON, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in two upcoming investor conferences in June.
5 months ago zacks.com
Down 17.2% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaround
LeMaitre (LMAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising…
-
5 months ago benzinga.com
Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $120
Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and raises the price target from $105 to $120.
-
5 months ago benzinga.com
Citizens Maintains Market Outperform on LeMaitre Vascular, Raises Price Target to $127
Citizens analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperform and raises the price target from $118 to $127.
-
5 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Raises Price Target to $104
Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight and raises the price target from $94 to $104.
-
6 months ago benzinga.com
LeMaitre Vascular Reports Q1 2026 Results: Full Earnings Call Transcript
LeMaitre Vascular Reports Q1 2026 Results: Full Earnings Call Transcript
-
6 months ago benzinga.com
LeMaitre Vascular Sees Q2 GAAP EPS $0.79-$0.84 vs $0.75 Est; Sees Sales $70.500M-$72.500M vs $71.105M Est
LeMaitre Vascular (NASDAQ:LMAT) is looking for Q2 GAAP EPS of $0.79-$0.84 vs $0.75 analyst estimate. sees sales of $70.500 million-$72.500 million vs $71.105 million analyst estimate.
-
6 months ago benzinga.com
LeMaitre Vascular Raises FY2026 GAAP EPS Guidance from $2.81-$3.01 to $2.93-$3.08 vs $2.90 Est; Narrows FY2026 Sales Guidance from $276.000M-$284.000M to $277.000M-$283.000M vs $279.492M Est
LeMaitre Vascular (NASDAQ:LMAT) raises FY2026 GAAP EPS guidance from $2.81-$3.01 to $2.93-$3.08 vs $2.90 analyst estimate. Narrows FY2026 sales outlook from $276.000 million-$284.000 million to…
-
6 months ago benzinga.com
LeMaitre Vascular Q1 EPS $0.68 Beats $0.66 Estimate, Sales $66.551M Beat $66.530M Estimate
LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.66 by 3.03 percent. This is a 41.67 percent increase over earnings of…
-
8 months ago benzinga.com
Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $105
Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and raises the price target from $95 to $105.
8 months ago benzinga.com
J M Smucker, Krispy Kreme, Shake Shack, Accenture And Other Big Stocks Moving Higher On Thursday
J M Smucker, Krispy Kreme, Shake Shack, Accenture And Other Big Stocks Moving Higher On Thursday
8 months ago benzinga.com
Breaking Down LeMaitre Vascular: 4 Analysts Share Their Views
Breaking Down LeMaitre Vascular: 4 Analysts Share Their Views
-
8 months ago benzinga.com
Roth Capital Reiterates Buy on LeMaitre Vascular, Raises Price Target to $117
Roth Capital analyst Kyle Bauser reiterates LeMaitre Vascular (NASDAQ:LMAT) with a Buy and raises the price target from $108 to $117.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
8 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Raises Price Target to $94
Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight and raises the price target from $87 to $94.
-
8 months ago benzinga.com
Citizens Maintains Market Outperform on LeMaitre Vascular, Raises Price Target to $118
Citizens analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperform and raises the price target from $113 to $118.
-
8 months ago benzinga.com
LeMaitre Vascular Sees FY2026 GAAP EPS $2.81-$3.01 vs $2.58 Est; Sees Sales $276.000M-$284.000M vs $270.499M Est
LeMaitre Vascular (NASDAQ:LMAT) is looking for FY2026 GAAP EPS of $2.81-$3.01 vs $2.58 analyst estimate. sees sales of $276.000 million-$284.000 million vs $270.499 million analyst estimate.
-
8 months ago benzinga.com
LeMaitre Vascular Sees Q1 GAAP EPS $0.64-$0.69 vs $0.61 Est; Sees Sales $65.600M-$67.600M vs $65.855M Est
LeMaitre Vascular (NASDAQ:LMAT) is looking for Q1 GAAP EPS of $0.64-$0.69 vs $0.61 analyst estimate. sees sales of $65.600 million-$67.600 million vs $65.855 million analyst estimate.
8 months ago benzinga.com
LeMaitre Vascular: Q4 Earnings Insights
LeMaitre Vascular: Q4 Earnings Insights
-
8 months ago benzinga.com
LeMaitre Vascular Q4 EPS $0.68 Beats $0.66 Estimate, Sales $64.453M Beat $62.823M Estimate
LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.66 by 2.41 percent. This is a 38.78 percent increase over earnings of…
-
8 months ago benzinga.com
Earnings Scheduled For February 25, 2026
Earnings Scheduled For February 25, 2026
8 months ago benzinga.com
Exploring LeMaitre Vascular's Earnings Expectations
Exploring LeMaitre Vascular's Earnings Expectations
-
8 months ago benzinga.com
Barrington Research Maintains Outperform on LeMaitre Vascular, Maintains $95 Price Target
Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and maintains $95 price target.